Randall Goodman, MD
Ophthalmology · Santa Maria, CANPI 1891788436
Payments from drug & device makers
Across 228 payments — averaging $46.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Carl Zeiss Meditec USA, Inc.$2K
- Alcon$2K
- Glaukos Corporation$932
- Sight Sciences, Inc.$393
- Sun Pharmaceutical Industries Inc.$277
- plus $2K from 22 others
What the payments were for
- Consulting fees$1,10010%
- Food & beverage$7,39170%
- Gifts$390%
- Other$2,04119%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 85 | $3,031 |
| Carl Zeiss Meditec USA, Inc. | 5 | $2,176 |
| Alcon | 40 | $2,132 |
| Glaukos Corporation | 18 | $932 |
| Sight Sciences, Inc. | 15 | $393 |
| Sun Pharmaceutical Industries Inc. | 13 | $277 |
| NEW World Medical,inc. | 5 | $233 |
| Oyster Point Pharma, Inc. | 3 | $173 |
| Aerie Pharmaceuticals, Inc. | 1 | $115 |
| Ivantis, Inc | 4 | $113 |
| Ellexiscience | 1 | $111 |
| Novartis | 6 | $103 |
| Amgen | 6 | $93 |
| Nova Eye, Inc. | 2 | $89 |
| Rayner Intraocular Lenses Limited | 3 | $88 |
| Carl Zeiss Meditec, Inc. | 1 | $76 |
| Bausch & Lomb Americas Inc. | 4 | $76 |
| Merz North America, Inc. | 2 | $74 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $54 |
| Kala Pharmaceuticals, Inc. | 2 | $44 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Rxsight Inc | 1 | $31 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $29 |
| Tarsus Pharmaceuticals, Inc. | 1 | $27 |
| Shire North American Group Inc | 1 | $19 |
| Dompe US, Inc. | 1 | $17 |
| Eyepoint US, Inc. | 1 | $13 |
| Iridex Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IOLMaster 700$2,041
- XEN GLAUCOMA TREATMENT SYSTEM$1,221
- DURYSTA$1,206
- LUMIGAN$1,100
- AcrySof IQ PanOptix$378
- LenSx$247
- Clareon$245
- iDose$244
- OMNI(R) SURGICAL SYSTEM (US)$157
- AcrySof IQ PanOptix UV IOL$145
- iStent inject Trabecular Micro-Bypass Stent System$145
- Kahook Dual Blade$140
- Streamline Surgical System$140
- Ahmed Glaucoma Valve$140
- ARGOS$125
- TYRVAYA$124
- Rocklatan$115
- Rhopressa$115
- ORA$114
- AcrySof IQ VIVITY IOL$107
How this compares
$10,571 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CequaCyclosporine | 54 | $67,746 |
| Cyclosporine | 46 | $32,500 |
| RestasisCyclosporine | 25 | $31,972 |
| MieboPerfluorohexyloctane/Pf | 32 | $24,365 |
| XiidraLifitegrast | 17 | $23,404 |
| LumiganBimatoprost | 32 | $17,721 |
| Brimonidine Tartrate | 203 | $16,668 |
| RhopressaNetarsudil Mesylate | 35 | $16,524 |
| RocklatanNetarsudil Mesylat/Latanoprost | 29 | $11,870 |
| BesivanceBesifloxacin Hcl | 50 | $10,820 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 55 | $9,545 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 33 | $8,645 |
| IlevroNepafenac | 24 | $8,529 |
| Latanoprost | 702 | $7,173 |
| ProlensaBromfenac Sodium | 21 | $7,023 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sun Pharmaceutical Industries Inc.Cequa | $277 | $67,74654 claims |
| AbbVieRestasis, Lumigan, Combigan | $3,031 | $54,29074 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $76 | $47,76949 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $115 | $28,39364 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa, Loteprednol Etabonate, Lotemax Sm | $54 | $26,468130 claims |
| AlconSimbrinza | $2,132 | $8,64533 claims |
| NovartisIlevro | $103 | $8,52924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Santa Maria
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.